Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
A phase 1/2 trial of REM-422 in salivary gland cancers, run by Remix Therapeutics, now recruiting.
Overview
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma is a phase 1/2 interventional study registered as NCT06118086 by Remix Therapeutics, with 125 participants planned, started 2023-12-20 and due to reach its primary completion in 2027-09-30. Interventions recorded: REM-422.
Setting
A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Phase
Phase 1/2
Sponsor
Remix Therapeutics
Registry
Enrolled
125
Similar pages
not linked directly; found by shared links- TrialClinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Shares Salivary gland cancers and the tag pipeline.
- TrialA Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
Shares Salivary gland cancers and the tag pipeline.
- TrialA Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Shares Salivary gland cancers and the tag pipeline.
- TreatmentGotistobart
Shares Salivary gland cancers and the tag pipeline.